BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18395459)

  • 41. Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms.
    Corey-Bloom J; Aikin AM; Gutierrez AM; Nadhem JS; Howell TL; Thomas EA
    Brain Res; 2017 Oct; 1673():102-110. PubMed ID: 28823953
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.
    Menalled LB; Kudwa AE; Oakeshott S; Farrar A; Paterson N; Filippov I; Miller S; Kwan M; Olsen M; Beltran J; Torello J; Fitzpatrick J; Mushlin R; Cox K; McConnell K; Mazzella M; He D; Osborne GF; Al-Nackkash R; Bates GP; Tuunanen P; Lehtimaki K; Brunner D; Ghavami A; Ramboz S; Park L; Macdonald D; Munoz-Sanjuan I; Howland D
    PLoS One; 2014; 9(6):e99520. PubMed ID: 24955833
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.
    Reick C; Ellrichmann G; Tsai T; Lee DH; Wiese S; Gold R; Saft C; Linker RA
    Exp Neurol; 2016 Nov; 285(Pt A):12-23. PubMed ID: 27587303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model.
    Chou SY; Lee YC; Chen HM; Chiang MC; Lai HL; Chang HH; Wu YC; Sun CN; Chien CL; Lin YS; Wang SC; Tung YY; Chang C; Chern Y
    J Neurochem; 2005 Apr; 93(2):310-20. PubMed ID: 15816854
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Iron activates microglia and directly stimulates indoleamine-2,3-dioxygenase activity in the N171-82Q mouse model of Huntington's disease.
    Donley DW; Realing M; Gigley JP; Fox JH
    PLoS One; 2021; 16(5):e0250606. PubMed ID: 33989290
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
    Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W
    Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adeno-Associated Viral Vector Serotype DJ-Mediated Overexpression of N171-82Q-Mutant Huntingtin in the Striatum of Juvenile Mice Is a New Model for Huntington's Disease.
    Jang M; Lee SE; Cho IH
    Front Cell Neurosci; 2018; 12():157. PubMed ID: 29946240
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Altered sensory experience exacerbates stable dendritic spine and synapse loss in a mouse model of Huntington's disease.
    Murmu RP; Li W; Szepesi Z; Li JY
    J Neurosci; 2015 Jan; 35(1):287-98. PubMed ID: 25568121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
    Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
    Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.
    Chaturvedi RK; Calingasan NY; Yang L; Hennessey T; Johri A; Beal MF
    Hum Mol Genet; 2010 Aug; 19(16):3190-205. PubMed ID: 20529956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease.
    Klivenyi P; Ferrante RJ; Gardian G; Browne S; Chabrier PE; Beal MF
    J Neurochem; 2003 Jul; 86(1):267-72. PubMed ID: 12807446
    [TBL] [Abstract][Full Text] [Related]  

  • 52. LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease.
    Chopra V; Quinti L; Khanna P; Paganetti P; Kuhn R; Young AB; Kazantsev AG; Hersch S
    J Huntingtons Dis; 2016 Dec; 5(4):347-355. PubMed ID: 27983565
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.
    Vamos E; Voros K; Vecsei L; Klivenyi P
    Biomed Pharmacother; 2010 Apr; 64(4):282-6. PubMed ID: 19932584
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
    Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
    Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase.
    Bailey CD; Johnson GV
    Neurobiol Aging; 2006 Jun; 27(6):871-9. PubMed ID: 15896882
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.
    Moffitt H; McPhail GD; Woodman B; Hobbs C; Bates GP
    PLoS One; 2009 Nov; 4(11):e8025. PubMed ID: 19956633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice.
    Jia H; Wang Y; Morris CD; Jacques V; Gottesfeld JM; Rusche JR; Thomas EA
    PLoS One; 2016; 11(3):e0152498. PubMed ID: 27031333
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic Effect of Berberine on Huntington's Disease Transgenic Mouse Model.
    Jiang W; Wei W; Gaertig MA; Li S; Li XJ
    PLoS One; 2015; 10(7):e0134142. PubMed ID: 26225560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Murine Models of Huntington's Disease for Evaluating Therapeutics.
    Kosior N; Leavitt BR
    Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice.
    Norflus F; Nanje A; Gutekunst CA; Shi G; Cohen J; Bejarano M; Fox J; Ferrante RJ; Hersch SM
    Neurobiol Dis; 2004 Nov; 17(2):319-25. PubMed ID: 15474369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.